MediWound (NASDAQ:MDWD – Get Free Report) announced its quarterly earnings results on Thursday. The biopharmaceutical company reported ($0.77) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.76) by ($0.01), Zacks reports. MediWound had a negative return on equity of 44.77% and a negative net margin of 170.10%.The firm had revenue of $3.09 million during the quarter, compared to the consensus estimate of $2.59 million.
Here are the key takeaways from MediWound’s conference call:
- EscharEx’s VALUE Phase III trial remains on track, with interim sample-size reassessment and enrollment completion targeted by the end of Q1 2027. The company says nearly all of the approximately 40 sites are recruiting.
- MediWound expanded its estimated U.S. peak annual sales opportunity for EscharEx to $1.05 billion after including pressure ulcers, and plans to start a 50-patient diabetic foot ulcer study and a small pressure-ulcer investigator-initiated study in Q4 2026.
- NexoBrid’s U.S. commercial adoption continued to improve, with Vericel reporting record quarterly revenue, hospital unit sales and ordering centers; approximately 80 U.S. burn centers have ordered the product since launch.
- The new master service agreement with Vericel is expected to begin contributing revenue in the second half of 2026, including development programs targeting blast and friction injuries. MediWound reaffirmed 2026 revenue guidance of $24 million–$26 million, weighted heavily toward the second half.
- Financial performance weakened in the first half: Q2 revenue fell to $3.1 million from $5.7 million year over year, while cash and deposits declined to approximately $36 million from $54 million at year-end 2025 after $20 million of first-half cash burn. R&D spending is expected to remain elevated as the VALUE trial advances, and expanded-facility commercial supply is not expected until the second half of 2027.
MediWound Stock Performance
MDWD traded up $0.03 during midday trading on Friday, reaching $13.56. 46,748 shares of the company were exchanged, compared to its average volume of 61,427. The company has a market cap of $174.25 million, a price-to-earnings ratio of -7.53 and a beta of 0.15. MediWound has a one year low of $13.40 and a one year high of $20.30. The company’s fifty day moving average price is $14.35 and its 200 day moving average price is $15.97.
Analyst Ratings Changes
Check Out Our Latest Stock Analysis on MediWound
Insider Buying and Selling at MediWound
In related news, Director David Morton Fox bought 3,537 shares of the business’s stock in a transaction that occurred on Monday, June 1st. The shares were bought at an average price of $14.11 per share, with a total value of $49,907.07. Following the completion of the transaction, the director directly owned 22,283 shares in the company, valued at approximately $314,413.13. This represents a 18.87% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. 9.20% of the stock is owned by corporate insiders.
Institutional Investors Weigh In On MediWound
A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Kotler Kevin purchased a new position in MediWound during the 4th quarter worth $6,225,000. Sphera Funds Management LTD. raised its holdings in shares of MediWound by 24.3% in the fourth quarter. Sphera Funds Management LTD. now owns 230,347 shares of the biopharmaceutical company’s stock valued at $4,252,000 after purchasing an additional 45,077 shares during the last quarter. Millennium Management LLC lifted its position in shares of MediWound by 355.6% during the third quarter. Millennium Management LLC now owns 175,383 shares of the biopharmaceutical company’s stock valued at $3,160,000 after purchasing an additional 136,884 shares in the last quarter. State Street Corp lifted its position in shares of MediWound by 10.7% during the fourth quarter. State Street Corp now owns 124,510 shares of the biopharmaceutical company’s stock valued at $2,298,000 after purchasing an additional 12,066 shares in the last quarter. Finally, Geode Capital Management LLC boosted its holdings in MediWound by 22.8% during the fourth quarter. Geode Capital Management LLC now owns 120,101 shares of the biopharmaceutical company’s stock worth $2,217,000 after purchasing an additional 22,268 shares during the last quarter. 46.83% of the stock is owned by hedge funds and other institutional investors.
MediWound Company Profile
MediWound Ltd. (NASDAQ: MDWD) is a biopharmaceutical company headquartered in Yavne, Israel, specializing in the development and commercialization of innovative enzymatic therapies for burn and wound management. Since its establishment, the company has focused on advancing proteolytic enzyme technology to address critical needs in debridement and tissue repair. MediWound operates research and development facilities in Israel and maintains commercial offices in the United States to support its global market presence.
The company’s lead product, NexoBrid®, is an enzyme-based debriding agent designed to selectively remove burn eschar without harming viable tissue.
Featured Stories
- Five stocks we like better than MediWound
- Is Best Buy the AI Winner Hiding in the Electronics Aisle?
- Applied Materials Beat Everything but Wall Street’s Expectations for Margins
- Back From Orbit, Intuitive Machines’ Share Price Enters the Buy Zone
- Texas Roadhouse and Brinker International Have the Recipe Rivals Are Missing
Receive News & Ratings for MediWound Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MediWound and related companies with MarketBeat.com's FREE daily email newsletter.
